Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Inclusion Criteria: * Body weight ≥40.0 kg and ≤100 kg at screening * Documented diagnosis of beta-thalassemia or Hb E/beta-thalassemia * Red blood cell (RBC) transfusion dependence, defined as at least 6 RBC units in the 24 weeks prior to randomization and no transfusion-free period for ≥35 days during that period * Ability to understand the requirements of the study and provide written informed consent Exclusion Criteria: * Documented diagnosis of Hb S/beta-thalassemia, alpha-thalassemia, or delta beta (δβ)-thalassemia, or hereditary persistence of foetal Hb. * History of partial or total splenectomy within 4 months prior to screening. * History of myocardial iron overload * Chronic liver disease or history of liver cirrhosis * Clinically relevant renal disease * History or clinically important finding of cardiac disorders * History of clinically significant lung disease * Uncontrolled hypertension (\> Grade 1 according to NCI CTCAE current version) * Unable to take and absorb oral medications. * Pregnancy or breastfeeding * History of drug or alcohol abuse within 2 years prior to screening * History or concomitant solid tumors and/or hematological malignancies unless resolved in the ≥5 past years.